Abstract:Background: Recent advances in the understanding of the molecular mechanisms underlying atopic dermatitis (AD) and psoriasis (PSO) have led to the development of multiple targeted therapies. Yet, molecular heterogeneity contributes to inconsistent clinical presentation and therapeutic response. Further, systemic treatment of presumed AD or PSO can lead to delays in both diagnosis and proper treatment of patients with a true diagnosis of mycosis fungoides (MF) – a potentially dangerous clinical mimic of AD and PSO that requires a rigorous histologic and molecular workup to diagnose. Therefore, a non-invasive method to distinguish molecular profiles of MF from AD and PSO could inform accurate diagnoses and avoid inappropriate treatment of MF. We have previously shown transcriptomic differences in AD and PSO samples obtained by a non-invasive scraping technique. However, this technique has not been used to assess differences in gene expression profiles of MF samples. Objectives: To identify gene expression differences based on diagnosis of MF, AD, or PSO and response to targeted systemic AD or PSO therapies. Methods: Lesional baseline samples were assessed from 76 patients (AD, n=24; PSO, n=48; and MF, n=4) enrolled in one of two IRB-approved studies (IDENTITY or SIGNAL-MF). Lesional samples were collected by epidermal scraping and preserved in RNA buffer. Library preparation and next generation RNA sequencing was performed using the Ion AmpliSeq Transcriptome Human Gene Expression panel on the S5 Prime sequencer (ThermoFisher). Clinical responses for AD and PSO were further assessed over 3 months using the eczema and psoriasis area and severity index (EASI and PASI, respectively). Genes were considered differentially expressed if there was a log2fold change >|1.0| and padj <.05. Results: Statistically significant differences in gene expression were observed between AD, PSO, and MF lesions. Further, genes were differentially expressed in baseline skin scrapings obtained from super-responders to dupilumab, which blocks both IL-4 and IL-13 signaling, and PSO therapies including the IL-23 inhibitor risankizumab relative to those who did not achieve ≥90% improvement. Conclusion: A non-invasive molecular test could be developed to distinguish between AD, PSO, and MF, and further identify super-responders to targeted PSO and AD therapies.

Intrapatient comparison of atopic dermatitis skin transcriptome shows differences between tape‐strips and biopsies

Identification of Candidate Genes in Atopic Dermatitis Based on Bioinformatic Methods

Minimally Invasive Skin Tape Strip RNA Sequencing Identifies Novel Characteristics of the Type 2-High Atopic Dermatitis Disease Endotype

Skin tape sampling technique identifies proinflammatory cytokines in atopic dermatitis skin

Multiple Transcriptome Data Analysis Reveals Biologically Relevant Atopic Dermatitis Signature Genes and Pathways

Spatial transcriptomics combined with single‐cell RNA‐sequencing unravels the complex inflammatory cell network in atopic dermatitis

Transcriptomics in atopic dermatitis

Single‐cell <scp>RNA</scp>‐seq reveals abnormal differentiation of keratinocytes and increased inflammatory differentiated keratinocytes in atopic dermatitis

Comparative Proteomics Analysis Reveals Distinct Molecular Phenotype and Biomarkers in Patients with Erythrodermic Atopic Dermatitis and Erythrodermic Psoriasis

Single‐cell profiles reveal distinctive immune response in atopic dermatitis in contrast to psoriasis

Gene Expression Differences Identified in Skin Samples of Mycosis Fungoides, Atopic Dermatitis, and Psoriasis

Identifying Immune Cell Infiltration and Constructing a Cerna Network to Explore Novel Diagnostic Biomarkers and Therapeutic Targets in Atopic Dermatitis

Epidermal renewal during the treatment of atopic dermatitis lesions: A study coupling line-field confocal optical coherence tomography with artificial intelligence quantifications: LC-OCT reveals new biological markers of AD

Cytokine profile of the stratum corneum in atopic dermatitis lesions differs between the face and the trunk

RNA-Seq Identifies Marked Th17 Cell Activation and Altered CFTR Expression in Different Atopic Dermatitis Subtypes in Chinese Han Populations

Genome-wide identification of dysregulated alternative splicing and RNA-binding proteins involved in atopic dermatitis

Skin microdialysis detects distinct immunological patterns in chronic inflammatory skin diseases

What is the discrepancy between drug permeation into/across intact and diseased skins? Atopic dermatitis as a model

Epidermal renewal during the treatment of atopic dermatitis lesions: A study coupling line‐field confocal optical coherence tomography with artificial intelligence quantifications

Identification of diagnostic molecules and potential therapeutic agents for atopic dermatitis by single-cell RNA sequencing combined with a systematic computing framework that integrates network pharmacology

Identification of novel candidate genes and predicted miRNAs in atopic dermatitis patients by bioinformatic methods